<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T01:47:37Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10256/28122" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10256/28122</identifier><datestamp>2026-01-17T00:56:36Z</datestamp><setSpec>com_2072_452955</setSpec><setSpec>com_2072_2054</setSpec><setSpec>col_2072_453073</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>A nucleus-directed bombesin derivative for targeted delivery of metallodrugs to cancer cells</dc:title>
   <dc:creator>Barrabés Vera, Sílvia</dc:creator>
   <dc:creator>Ng-Choi, Iteng</dc:creator>
   <dc:creator>Martínez Lorente, Mª Ángeles</dc:creator>
   <dc:creator>Manzano, Blanca R.</dc:creator>
   <dc:creator>Jalón, Félix A.</dc:creator>
   <dc:creator>Espino, Gustavo</dc:creator>
   <dc:creator>Feliu Soley, Lidia</dc:creator>
   <dc:creator>Planas i Grabuleda, Marta</dc:creator>
   <dc:creator>Llorens Duran, Rafael de</dc:creator>
   <dc:creator>Massaguer i Vall-llovera, Anna</dc:creator>
   <dc:contributor>Agencia Estatal de Investigación</dc:contributor>
   <dc:subject>Bombesina -- Síntesi</dc:subject>
   <dc:subject>Bombesin -- Synthesis</dc:subject>
   <dc:subject>Medicaments antineoplàstics</dc:subject>
   <dc:subject>Antineoplastic agents</dc:subject>
   <dc:subject>Cèl·lules canceroses</dc:subject>
   <dc:subject>Cancer cells</dc:subject>
   <dc:description>We have synthesized a set of bombesin derivatives with the aim of exploring their tumor targeting properties to deliver metal-based chemotherapeutics into cancer cells. Peptide QRLGNQWAVGHLL-NH2 (BN3) was selected based on its high internalization in gastrin-releasing peptide receptor (GRPR)-overexpressing PC-3 cells. Three metallopeptides were prepared by incorporating the terpyridine Pt(II) complex [PtCl(cptpy)]Cl (1) (cptpy = 4′-(4-carboxyphenyl)-2,2′:6,2″-terpyridine) at the N-terminus of BN3 or at the NƐ- or Nα-amino group of an additional Lys residue (1-BN3, Lys-1-BN3 and 1-Lys-BN3, respectively). 1-Lys-BN3 displayed the best cytotoxic activity (IC50: 19.2 ± 1.7 μM) and similar ability to intercalate into DNA than complex 1. Moreover, the polypyridine Ru(II) complex [Ru(bpy)2)(cmbpy)](PF6)2 (2) (bpy = 2,2′-bipyridine; cmbpy = 4-methyl-2,2′-bipyridine-4′-carboxylic acid), with proven activity as photosensitizer, was coupled to BN3 leading to metallopeptide 2-Lys-BN3. Upon photoactivation, 2-Lys-BN3 displayed 2.5-fold higher cytotoxicity against PC-3 cells (IC50: 7.6 ± 1.0 μM) than complex 2. To enhance the accumulation of the drugs into the cell nucleus, the nuclear localization signal (NLS) PKKKRKV was incorporated at the N-terminus of BN3. NLS-BN3 displayed higher cellular internalization along with nuclear biodistribution. Accordingly, metallopeptides 1-NLS-BN3 and 2-NLS-BN3 showed increased cytotoxicity (IC50: 12.0 ± 1.1 μM and 2.3 ± 1.1 μM). Interestingly, the phototoxic index of 2-NLS-BN3 was 8-fold higher than that of complex 2. Next, the selectivity towards cancer cells was explored using 1BR3.G fibroblasts. Higher selectivity indexes were obtained for 1-NLS-BN3 and 2-NLS-BN3 than for the unconjugated complexes. These results prove NLS-BN3 effective for targeted delivery of metallodrugs to GRPR-overexpressing cells and for enhancing the cytotoxic efficacy of metal-based photosensitizers</dc:description>
   <dc:description>This work was supported by the University of Girona (grants MPCUdG2016/038 and MPCUdG2016/076); the Spanish Ministerio de Ciencia, Innovación y Universidades (grants RTI2018-100709-B-C21 and RTI2018-100709-B-C22) and Junta de Castilla La Mancha-FEDER funds (SBPLY/19/180501/000260)</dc:description>
   <dc:date>2020-11</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
   <dc:type>peer-reviewed</dc:type>
   <dc:identifier>http://hdl.handle.net/10256/28122</dc:identifier>
   <dc:identifier>32919249</dc:identifier>
   <dc:identifier>http://hdl.handle.net/10256/28122</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinorgbio.2020.111214</dc:relation>
   <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0162-0134</dc:relation>
   <dc:relation>info:eu-repo/semantics/altIdentifier/eissn/1873-3344</dc:relation>
   <dc:relation>RTI2018-100709-B-C22</dc:relation>
   <dc:relation>info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-100709-B-C22/ES/NUEVOS METALOFARMACOS DISEÑADOS PARA INCREMENTAR LA SELECTIVIDAD. USO DE FOTOTERAPIA Y VEHICULIZACION CON LIGANDOS DIRIGIDOS A TUMORES/</dc:relation>
   <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Elsevier</dc:publisher>
   <dc:source>© Journal of Inorganic Biochemistry, 2020, vol. 212, art. núm. 111214</dc:source>
   <dc:source>Articles publicats (D-Q)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>